Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma
-
- Victor A. Chow
- Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA;
-
- Mazyar Shadman
- Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA;
-
- Ajay K. Gopal
- Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA;
抄録
<jats:title>Abstract</jats:title> <jats:p>Chimeric antigen receptor T cells demonstrate efficacy in B-cell malignancies, leading to US Food and Drug Administration approval of axicabtagene ciloleucel (October 2017) and tisagenlecleucel (May 2018) for large B-cell lymphomas after 2 prior lines of therapy. Durable remissions are seen in 30% to 40% of study-treated patients, but toxicities of cytokine release syndrome and neurotoxicity require administration in specialized centers. This article reviews data of current diffuse large B-cell lymphoma management, focusing on axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel.</jats:p>
収録刊行物
-
- Blood
-
Blood 132 (8), 777-781, 2018-08-23
American Society of Hematology